Business
CK1d Update: Toxicity Results
CK1d Update: Toxicity Results.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 6595S Proteome Sciences PLC 26 September 2014 \n \n\n \n \n \n \nProteome Sciences plc\n \nExcellent Toxicity Results for PS110 and PS278-05 in Alzheimer's disease\n \n26th September 2014. Proteome Sciences is very pleased to announce that the two external in vitro toxicity safety tests (Ames and Cyp) have shown no adverse data for either of the two lead compounds, PS110 and PS278-05 for its CK1d programme which has demonstrated the modification of the tau pathway in Alzheimer's disease.\nGiven the current strong pharma interest in secretases, initially gamma secretase and lately beta secretase (BACE) this entirely unrelated series gives another powerful approach to potential Alzheimer therapies.\nThese lead molecules have shown in vivo activity in a relevant mouse model and much mechanistic data has been collected confirming the validity of tau as a target in the treatment of this problematic dementia which is seen as one of the key areas for governmental support. We are also reporting the completion of the first SysQuant® study in CNS which has shown that our CK1d compounds have successfully modified certain key pathways linked with amyloid processing, oxidative phosphorylation and energy production and these have reduced tau damage in our preferred in vivo mouse model.\nOur aim was to achieve data that reflected efficacy, to provide early safety data and to ensure that the patent portfolio was strong. With this CK1d portfolio we are ready to move into the next stage of marketing to progress the outlicensing programme with pharma following on from the presentations made at the Alzheimer's Association International Conference (AAIC) in July. Our strategy is to partner the CK1d compounds with pharma on the back of these results.\nDr Ian Pike, COO commented: &...